Cogent Biosciences Book Value Per Share Growth & History (COGT)
Cogent Biosciences's book value per share was $3.40 for fiscal 2025.
View full Cogent Biosciences company overviewCogent Biosciences annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.40 | $2.08 | +157.63% |
| 2024 | 2024-12-31 | $1.32 | -$0.98 | −42.56% |
| 2023 | 2023-12-31 | $2.30 | -$0.42 | −15.49% |
| 2022 | 2022-12-31 | $2.72 | -$2.17 | −44.43% |
| 2021 | 2021-12-31 | $4.89 | -$2.37 | −32.60% |
| 2020 | 2020-12-31 | $7.25 | $3.11 | +75.09% |
| 2019 | 2019-12-31 | $4.14 | -$3.87 | −48.31% |
| 2018 | 2018-12-31 | $8.02 | $27.17 | — |
| 2017 | 2017-12-31 | -$19.15 | — | — |
Cogent Biosciences quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.73 | $2.31 | +558.89% |
| Q1 2026 | 2026-03-31 | $3.18 | $2.21 | +226.61% |
| Q4 2025 | 2025-12-31 | $3.40 | $1.08 | +46.45% |
| Q3 2025 | 2025-09-30 | $1.39 | -$1.46 | −51.16% |
| Q2 2025 | 2025-06-30 | $0.41 | -$3.00 | −87.88% |
| Q1 2025 | 2025-03-31 | $0.97 | -$3.44 | −77.96% |
| Q4 2024 | 2024-12-31 | $2.32 | -$0.67 | −22.49% |
| Q3 2024 | 2024-09-30 | $2.85 | -$0.67 | −19.00% |
| Q2 2024 | 2024-06-30 | $3.41 | -$0.67 | −16.40% |
| Q1 2024 | 2024-03-31 | $4.42 | $1.27 | +40.17% |
| Q4 2023 | 2023-12-31 | $2.99 | -$0.67 | −18.19% |
| Q3 2023 | 2023-09-30 | $3.52 | -$0.63 | −15.26% |
| Q2 2023 | 2023-06-30 | $4.08 | -$0.78 | −16.00% |
| Q1 2023 | 2023-03-31 | $3.15 | -$0.95 | −23.14% |
| Q4 2022 | 2022-12-31 | $3.66 | -$1.23 | −25.17% |
| Q3 2022 | 2022-09-30 | $4.15 | -$0.80 | −16.14% |
| Q2 2022 | 2022-06-30 | $4.86 | -$0.48 | −9.02% |
| Q1 2022 | 2022-03-31 | $4.10 | -$2.00 | −32.75% |
| Q4 2021 | 2021-12-31 | $4.89 | -$2.37 | −32.60% |
| Q3 2021 | 2021-09-30 | $4.95 | $7.03 | — |
| Q2 2021 | 2021-06-30 | $5.34 | $2.87 | +116.32% |
| Q1 2021 | 2021-03-31 | $6.10 | $2.76 | +82.78% |
| Q4 2020 | 2020-12-31 | $7.25 | $3.11 | +75.09% |
| Q3 2020 | 2020-09-30 | -$2.08 | -$5.81 | — |
| Q2 2020 | 2020-06-30 | $2.47 | -$2.72 | −52.38% |
| Q1 2020 | 2020-03-31 | $3.34 | -$3.21 | −49.05% |
| Q4 2019 | 2019-12-31 | $4.14 | -$3.87 | −48.31% |
| Q3 2019 | 2019-09-30 | $3.73 | -$5.29 | −58.64% |
| Q2 2019 | 2019-06-30 | $5.19 | -$5.08 | −49.49% |
| Q1 2019 | 2019-03-31 | $6.55 | $30.55 | — |
| Q4 2018 | 2018-12-31 | $8.02 | $27.17 | — |
| Q3 2018 | 2018-09-30 | $9.03 | — | — |
| Q2 2018 | 2018-06-30 | $10.27 | — | — |
| Q1 2018 | 2018-03-31 | -$24.01 | — | — |
| Q4 2017 | 2017-12-31 | -$19.15 | — | — |
Cogent Biosciences book value per share trends
Over the last five fiscal years, Cogent Biosciences's book value per share decreased from $7.25 to $3.40, a change of -$3.86. The latest reported quarter, Q2 2026, shows $2.73.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cogent Biosciences source filings ↗